Overview: Synaptophysin Immunohistochemistry TestIntroduction: The Synaptophysin Immunohistochemistry Test detects synaptophysin to diagnose neuroendocrine tumors, causing hormonal imbalances or pain. Aligned with 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected neuroendocrine tumors.
Other Names: Synaptophysin IHC Assay, Neuroendocrine Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Synaptophysin testing began in the 1980s with neuroendocrine research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects synaptophysin to diagnose neuroendocrine tumors, guides treatment, and evaluates patients with hormonal imbalances or pain.
Test Parameters: 1. Synaptophysin Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of hormonal imbalances, pain, or flushing.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document hormonal imbalances, pain, flushing, or family history of neuroendocrine tumors. Include current medications, especially somatostatin analogs.
Consent: Written consent required, detailing the tests purpose, tumor implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect synaptophysin in tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for neuroendocrine tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive synaptophysin staining confirms neuroendocrine tumors, guiding surgery or medical therapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Chromogranin A IHC, serum chromogranin A, or PET-CT to confirm neuroendocrine tumor diagnosis.
Test Limitations: Not specific to one neuroendocrine tumor; other conditions may express synaptophysin. Clinical correlation is needed.
References: NCCN Neuroendocrine Tumor Guidelines, 2023; American Journal of Surgical Pathology, Klimstra DS, 2022.
